TOKYO, May 12 (Pulse News Wire) – JMS CO.,LTD. (7702.T) reported mixed results for its fiscal year ending March 31, 2026.
Revenue decreased by 11.4% to ¥447 billion compared to the previous fiscal year due to reduced sales of acute blood purification devices and Chinese dialysis equipment. Operating profit declined by 20.7%, while ordinary profit fell by 21.3%. However, lower net profit widened significantly to -¥783 million from a net income of ¥89 million in the prior year. For the next fiscal year ending March 31, 2027, the company forecasts revenue growth of 0.2% to ¥448 billion, driven by anticipated recovery and expansion in overseas markets.
Operating profit is expected to improve to ¥162.1 million, up from the current forecast of ¥381 million. In addition, JMS plans to build a new headquarters facility to address aging infrastructure and enhance research capabilities. Construction is set to begin in February 2027, with completion scheduled for August 2028, though the new office building alone will be ready by December 2027. The impact on future performance remains under assessment.
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥65,845M | -5.6% |
| Operating profit | ¥381M | -56.3% |
| Net profit | ¥-783M | n/a |
Next period forecast
Revenue
¥66,000M
+0.2%Op. profit
¥1,000M
+162.1%Net profit
¥600M
+24.5%Source: TDNet filing · Figures in millions of yen
🟡 Confidence: Standard AI-translated content.